Ranibizumab: The evidence of its therapeutic value in neovascular age-related macular degeneration

Core Evidence

Volumn 2, Issue 4, 2008, Pages 273-294

  Kaiser, Peter K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Evidence; Neovascular age related macular degeneration; Ranibizumab

Indexed keywords

AG 013958; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANECORTAVE; ARACHIDONIC ACID; BEVACIZUMAB; BEVASIRINIB; CAND 5; COMPLEMENT COMPONENT C2; COMPLEMENT FACTOR H; DRUG ANTIBODY; MINERAL; PAZOPANIB; PEGAPTANIB; PHOSPHOLIPASE A2; PIGMENT EPITHELIUM DERIVED FACTOR; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; RAPAMYCIN; SIRNA 027; SMALL INTERFERING RNA; STEROID; STRONTIUM 90; TG 100801; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VATALANIB; VERTEPORFIN; VITAMIN;

ANTIANGIOGENIC ACTIVITY; ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; BRACHYTHERAPY; CATARACT; CIGARETTE SMOKING; CLINICAL DECISION MAKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIET SUPPLEMENTATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUSEN; ELECTRON THERAPY; ENDOPHTHALMITIS; EVIDENCE BASED MEDICINE; EYE DISEASE; EYE INFLAMMATION; GENETIC RISK; HEART INFARCTION; HEREDITY; HUMAN; INJECTION SITE BLEEDING; INTRAOCULAR HYPERTENSION; LASER COAGULATION; LENS DISEASE; MONOTHERAPY; NONHUMAN; NUCLEOTIDE SEQUENCE; OFF LABEL DRUG USE; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; PROGNOSIS; PROTEIN EXPRESSION; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETINA PIGMENT EPITHELIOPATHY; RETINA TEAR; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; STROKE; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC DISEASE; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UVEITIS; VASCULAR DISEASE; VISUAL ACUITY; VITREOUS HEMORRHAGE;

EID: 54749136955     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Aiello LF, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
2. AAO (American Academy of Ophthalmology Retina Panel). Age-related macular degeneration limited revision preferred practice pattern. 2006. Available at: http://www.aao.org/education/guidelines/ppp/ amd_,new.cfm (accessed May 31, 2007).
3. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002;134:411-431.
4. Anon. Lucentis Prescribing Information, Available at: www.gene.com (accessed April 25, 2007a).
5. Anon. Lucentis/SAILOR dear healthcare provider letter. Available at: http://www.gene.com/gene/products/information/pdf/ healthcare-provider-letter.pdf (accessed April 25, 2007b).
6. AOA (American Optometric Association) Consensus Panel on Care of the Patient With Age-Related Macular Degeneration. Optometric clinical practice guideline: care of the patient with age-related macular degeneration. 2004. Available at: http://www.aoa.org/documents/ CPG-6.pdf (accessed June 5, 2007).
7. AREDS (Age-Related Eye Disease Study Research Group). The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1. Control Clin Trials. 1999;20:573-600,
8. AREDS (Age-Related Eye Disease Study Research Group). Risk factors associated with age-related macular degeneration: a case-control study in the Age-Related Eye Disease Study. Age-Related Eye Disease Study report number 3. Ophthalmology. 2000;107:2224-2232.
9. AREDS (Age-Related Eye Disease Study Research Group). A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417-1436.
10. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372.
11. Barbazetto I, Burdan A, Bressler NM, et al. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group; Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2. Arch Ophthalmol. 2003;121:1253-1268.
12. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;142:1-9.
13. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR; MARINA Study Group, Subgroup analysis of the MARINA study of ranibizumab in neovascular age-retated macular degeneration. Ophthalmology. 2007;114:246-252.
14. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol. 2001;119:198-207.
15. Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol. 2000;118:47-51.
16. Brown GC, Brown MM, Sharma S, et al. The burden of age-related macular degeneration: a value-based medicine analysis. Trans Am Cphthalmol Soc. 2005;103:173-184.
17. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group, Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
18. Brown DM, Yue H, Shams N. Ranibizumab (Lucentis) in neovascular age-related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Presented at: Association for Research in Vision and Ophthalmology Annual Meeting; May 6-10, 2007a; Fort Lauderdale, FL. Abstract 4540. Available at: http://www.arvo.org (accessed April 26, 2007).
19. Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. Ophthalmology. 2007b;114:1170-1178.
20. Brown MM, Brown GC, Brown H. Value-based medicine and interventions for macular degeneration. Curr Opin Ophthalmol. 2007c;18:194-200.
21. Brown MM, Brown GC. Value-based medicine: the clear case for quality standards. Evidence Based Ophthalmol. 2007;6:181-182.
22. Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther. 2006;17:167-176.
23. Chang TS, Fine JT, Bressler N. Self-reported vision-specific quality of life at 1 year in patients with neovascular age-related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis). Presented at: Association for Research in Vision and Ophthalmology Annual Meeting; April 30-May 4, 2006, Fort Lauderdale, FL. Abstract 5252. Available at: http://www.arvo.org (accessed April 26,2007).
24. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J. Self-reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Presented at: Association for Research in Vision and Ophthalmology Annual Meeting; May 6-10, 2007; Fort Lauderdale, FIL. Abstract 1830. Available at: http://www.arvo.org (accessed April 26, 2007).
25. Dejneka NS, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis. 2004;10:964-972.
26. de Jong PT. Age-related macular degeneration. N Engl J Med. 2006;355:1474-1485.
27. DeWan A, Liu M, Hartman S, et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science. 2006;314:989-992.
28. Donoso LA, Kim D, Frost A, Callahan A, Hageman G. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2006;51:137-152.
29. Fine SL, Berger JW, Maguire MG, Ho AC. Age-related macular degeneration. N Engl J Med. 2000;342:483-492.
30. Friedman DS, O'Colmain BJ, Muñoz B, et al; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004:122:564-572.
31. Fung AE, Lalwani GA, Michels S, et al. Characteristics of patients losing vision at year 1 of the PrONTO study. Presented at: Association for Research in Vision and Ophthalmology Annual Meeting; May 6-10, 2007a; Fort Lauderdale, FL. Abstract 4579. Available at: http://www.arvo.org (accessed April 26, 2007).
32. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007b;143:566-583.
33. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinicai pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46:726-733.
34. Giles MC, Wong TY. Correspondence: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2007;356:74B-749.
35. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
36. Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Net Genet. 2006;38:458-462.
37. Haddad S, Chen CA, Santangelo SL, Seddon JIM. The genetics of age-related macular degeneration: a review of progress to date. Surv Ophthalmol. 2006;51:316-363.
38. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20:705-732.
39. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natt Acad Sci USA. 2005;102:7227-7232.
40. Hammond BR, Wooten BR, Snodderly DM. Cigarette smoking and retinal carotenoids: implications for age-related macular degeneration. Vision Res. 1996;36:3003-3009.
41. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006a;113:642.
42. Heier JS, Boyer DS, Ciulla TA et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol. 2006b;124:1532-1542.
43. Heier JS, Chung C, Schneider S; ANCHOR Study Group. Time course of visual acuity changes with ranibizumab (LucentiS™) in the 2-year ANCHOR study of patients with neovascular age-related macular degeneration (AMD). Presented at: Association for Research in Vision and Ophthalmology Annual Meeting; May 6-10, 2007; Fort Lauderdale, FL. Abstract 2872. Available at http://www.arvo,org (accessed April 26, 2007).
44. Jakobsdottir J, Conley YP, Weeks DE, Mah TS, Ferrell RE, Gorin MB, Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet. 2005;77:389-407.
45. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthatmol. 2006a;142:660-668.
46. Kaiser PK; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol. 2006b;244:1132-1142.
47. Kaiser PK, Yue H, Shams N. Subgroup analyses of one-year results of the PIER study of ranibizumab in neovascular AMD. Presented at: American Academy of Ophthalmology Annual Meeting; November 11-14, 2006c; Las Vegas, NV. Abstract PA058. Available at: http://www.aao.org (accessed April 26, 2007),
48. Kaiser PK, Do DV. Ranibizumab for the treatment of neovascular AMD. Int J Clin Pract. 2DO7;61:501-509.
49. Kaiser PK, Blodi BA, Shapiro H, Acharya NR; MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:1868-1875.
50. Kanda A, Chen W, Othman M, et al. A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc Natl Acad Sci USA. 2007:104:16227-16232.
51. Kirwan JF, Constable PH, Murdoch IE, Khaw PT. Beta irradiation: new uses for an old treatment: a review. Eye, 2003;17:207-215.
52. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992;99:933-943.
53. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-reiated macular degeneration. Am J Ophthalmol. 2004;137:486-495.
54. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997;81:154-162.
55. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002; 120:338-346.
56. Kuehn BM. Gene discovery provides clues to cause of age-related macular degeneration, JAMA. 2005;293:1841-1845.
57. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:1929-1934.
58. Lanzetta P; FOCUS Study Group. Combination intravitreal ranibizumab 0.5 mg and verteporfin PDT versus verteporfin PDT alone in the FOCUS study of neovascutar age-related macular degeneration (AMD). Presented at: Association for Research in Vision and Ophthalmology Annual Meeting; May 6-10, 2007; Fort Lauderdale, FL. Abstract 2869. Available at: http://www.arvo,org (accessed April 26, 2007).
59. Liew G, Mitchell P. Correspondence: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2007;356:747-748.
60. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035-1047.
61. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 1251-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27:536-544.
62. Morris B, Imrie F, Armbrecht AM, Dhillon B. Age-related macular degeneration and recent developments: new hope for old eyes? Postgrad Med J. 2007;83:301-307.
63. Moshfeghi DM, Blumenkranz MS. Role of genetic factors and inflammation in age-related macular degeneration. Retina. 2007;27:269-275.
64. MPS (Macular Photocoagulation Study Group). Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the macular photoccagulation study. Arch Ophthalmol. 1991;109:1242-1257.
65. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000;14:835--846.
66. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep. 2006;58:353-363.
67. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest. 1995;72:638-645.
68. Pleis JR, Lethbridge-Çejku M. Summary health statistics for U.S. adults: national health interview survey, 2005. National Center for Health Statistics; 2006. Vital Health Stat series 10 number 232. Available at: http://www.cdc.gov (accessed July 10, 2007),
69. Raftery J, Clegg A, Jones J, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol. 2007;91:1244-1246.
70. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335.
71. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006a;355:1419-1431.
72. Rosenfeld PJ, Fung AE, Lalwani GA, et al. Visual acuity outcomes following a variable-dosing regimen for ranibizumab (LucentiS™) in neovascular AMD: the PrONTO study. Presented at: Association for Research in Vision and Ophthalmology Annual Meeting; April 30-May 4, 2006b; Fort Lauderdale, FL. Abstract 2958. Available at: http://www.arvo.org (accessed April 26, 2007).
73. Rosenfeld PJ, Brown DM, Schneider, S; MARINA and ANCHOR Study Groups. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2007;356:749-750.
74. Ross RJ, Verma V, Rosenberg KI, Chan CC, Tuo J. Genetic markers and biomarkers for age-related macular degeneration. Expert Rev Ophthalmol. 2007:2;443-457.
75. Ruiz-Moreno JM, Montero JA, Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 2-year outcome. Retina. 2007;27:458-461.
76. Russell SR, Mullins RF, Schneider BL, Hageman GS. Location, substructure, and composition of basal laminar drusen compared with drusen associated with aging and age-related macular degeneration. Am J Ophthalmol. 2000;129:205-214.
77. SanGiovanni JP, Chew EY, Clemons TE, et al; Age-Related Eye Disease Study Research Group. The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS Report No. 20. Arch Ophthalmol. 2007;125:671-679.
78. Sastry BV, Hemontolor ME. Influence of nicotine and cotinine on retinal phospholipase A2 and its significance to macular function. J Ocul Pharmacol Ther. 1998;14:447-458,
79. Schmidt S, Hauser MA, Scott WK, et al, Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. Am J Hum Genet. 2006;76:852-864.
80. Schmidt-Erfurth UM, Gabel P, Hohman T, PROTECT Study Group. Preliminary results from an open-label, multicenter, phase II study assessing the effects of same-day administration of ranibizumab (Lucentis™) and verteporfin PDT (PROTECT Study). Presented at: Association for Research in Vision and Ophthalmology Annual Meeting; April 30-May 4, 2006; Fort Lauderdale, FL. Abstract 2960. Available at: http://www.arvo.org (accessed April 26, 2007).
81. Schwartz SG, Bressler NM, Fine JT, et al. Patient-reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Presented at: Association for Research in Vision and Ophthalmology Annual Meeting; May 6-10, 2007; Fort Lauderdale, FIL. Abstract 1822. Available at: http://www.arvo.org (accessed April 26, 2007).
82. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avartin). Retina. 2006;26:262-269.
83. Slakter JS, Bochow TW, D'Amico DJ, et al; Anecortave Acetate Clinical Study Group. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology. 2006;113:3-13.
84. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383-390.
85. Steinbrook R. The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006,355:1409-1412.
86. Stone EM. A very effective treatment for neovascular macular degeneration. N Enql J Med. 2006;355:1493-1495.
87. Suner IJ, Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: 24 month results from MARINA. Presented at: Association for Research in Vision and Ophthalmology Annual Meeting; May 6-10, 2007; Fort Lauderdale, FL. Abstract 1808. Available at: http://www.arvo.org (accessed April 26, 2007).
88. TAP (Treatment of Age-Related Macular Degeneration with Photodynamic Therapy) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical triats--TAP report. Arch Ophthalmol. 1999;117:1329-1345.
89. Tomany SC, Wang JJ, Van Leeuwen R, et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology. 2004;111:1280-1287.
90. VIP (Verteporfin In Photodynamic Therapy) Study Group. Verteporfin therapy of subfoveal choroical neovascularization in age-reiated macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541-560.
91. Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol. 1996;80:363-366.
92. Wolf S, Gabel R Hohman TC, et al; PROTECT Study Group. Fluorescein angiographic and OCT results from an open-label, multicenter, phase II study assessing the effects of same-day ranibizurnab (Lucentis™) and verteporfin PDT (Visudyne®). Presented at: Association for Research in Vision and Ophthalmology Annual Meeting; April 30-May 4, 2006; Fort Lauderdale, FL. Abstract 3542. Available at: http://www.arvo.org (accessed April 26, 2007).
93. Yang Z, Camp NJ, Sun H, et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science. 2006;314:992-993.
94. Yates JR, Sepp T, Matharu BK, et al; Genetic Factors in AMD Study Group. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007;357:553-561.
95. Zhou J, Jang YP, Kim SR, Sparrow JR. Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc Natt Acad Sci USA. 2006;103:16182-16187.